Benjamin A. Satterfield

Benjamin A. Satterfield

Auto-generated profile, based on publicly available information

Benjamin A. Satterfield

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2016 in Scientific Reports
Verified
Journal Article
Open access
CMChad E. Mire
Chad E. Mire
BSBenjamin A. Satterfield
Benjamin A. Satterfield
JGJoan B. Geisbert
Joan B. Geisbert
KAKrystle N. Agans
Krystle N. Agans
VBViktoriya Borisevich
Viktoriya Borisevich
Thomas W GeisbertThomas W Geisbert
Thomas W Geisbert
Nipah virus (NiV) is a paramyxovirus that causes severe disease in humans and animals. There are two distinct strains of NiV, Malaysia (NiVM) and Bangladesh (NiVB). Differences in transmission patterns and mortality rates suggest that NiVB may be more pathogenic than NiVM. To investigate pathogenic differences between strains, 4 African green monkeys (AGM) were exposed to NiVM and 4 AGMs were exposed to NiVB. While NiVB was uniformly lethal, only 50% of NiVM-infected animals succumbed to infection. Histopathology of lungs and spleens from NiVB-infected AGMs was significantly more severe than NiVM-infected animals. Importantly, a second study utilizing 11 AGMs showed that the therapeutic window for human monoclonal antibody m102.4, previously shown to rescue AGMs from NiVM infection, was much shorter in NiVB-infected AGMs. Together, these data show that NiVB is more pathogenic in AGMs under identical experimental conditions and suggests that postexposure treatments may need to be NiV strain specific for optimal efficacy.

14 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMichael G. Levin
Michael G. Levin
NTNoah L. Tsao
Noah L. Tsao
PSPankhuri Singhal
Pankhuri Singhal
CLChang Liu
Chang Liu
HVHa My T. Vy
Ha My T. Vy
SDScott M. Damrauer
Scott M. Damrauer
Heart failure is a leading cause of cardiovascular morbidity and mortality. However, the contribution of common genetic variation to heart failure risk has not been fully elucidated, particularly in comparison to other common cardiometabolic traits. We report a multi-ancestry genome-wide association study meta-analysis of all-cause heart failure including up to 115,150 cases and 1,550,331 controls of diverse genetic ancestry, identifying 47 risk loci. We also perform multivariate genome-wide association studies that integrate heart failure with related cardiac magnetic resonance imaging endophenotypes, identifying 61 risk loci. Gene-prioritization analyses including colocalization and transcriptome-wide association studies identify known and previously unreported candidate cardiomyopathy genes and cellular processes, which we validate in gene-expression profiling of failing and healthy human hearts. Colocalization, gene expression profiling, and Mendelian randomization provide convergent evidence for the roles of BCKDHA and circulating branch-chain amino acids in heart failure and cardiac structure. Finally, proteome-wide Mendelian randomization identifies 9 circulating proteins associated with heart failure or quantitative imaging traits. These analyses highlight similarities and differences among heart failure and associated cardiovascular imaging endophenotypes, implicate common genetic variation in the pathogenesis of heart failure, and identify circulating proteins that may represent cardiomyopathy treatment targets.

24 June 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBenjamin A. Satterfield
Benjamin A. Satterfield
RCRobert W. Cross
Robert W. Cross
KFKarla A. Fenton
Karla A. Fenton
KAKrystle N. Agans
Krystle N. Agans
CBChristopher F Basler
Christopher F Basler
CMChad E. Mire
Chad E. Mire
The viral determinants that contribute to Nipah virus (NiV)-mediated disease are poorly understood compared with other paramyxoviruses. Here we use recombinant NiVs (rNiVs) to examine the contributions of the NiV V and W proteins to NiV pathogenesis in a ferret model. We show that a V-deficient rNiV is susceptible to the innate immune response in vitro and behaves as a replicating non-lethal virus in vivo. Remarkably, rNiV lacking W expression results in a delayed and altered disease course with decreased respiratory disease and increased terminal neurological disease associated with altered in vitro inflammatory cytokine production. This study confirms the V protein as the major determinant of pathogenesis, also being the first in vivo study to show that the W protein modulates the inflammatory host immune response in a manner that determines the disease course.

22 October 2021 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
BSBenjamin A. Satterfield
Benjamin A. Satterfield
DBDeepak L Bhatt
Deepak L Bhatt
BGBernard J. Gersh
Bernard J. Gersh

1 June 2016 in Vaccine
Verified
Journal Article
Open access
BSBenjamin A. Satterfield
Benjamin A. Satterfield
BDBrian E Dawes
Brian E Dawes
GMGregg N. Milligan
Gregg N. Milligan
Nipah virus (NiV) is a highly pathogenic, recently emerged paramyxovirus that has been responsible for sporadic outbreaks of respiratory and encephalitic disease in Southeast Asia. High case fatality rates have also been associated with recent outbreaks in Malaysia and Bangladesh. Although over two billion people currently live in regions in which NiV is endemic or in which the Pteropus fruit bat reservoir is commonly found, there is no approved vaccine to protect against NiV disease. This report examines the feasibility and current efforts to develop a NiV vaccine including potential hurdles for technical and regulatory assessment of candidate vaccines and the likelihood for financing.

23 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMChad E. Mire
Chad E. Mire
JGJoan B. Geisbert
Joan B. Geisbert
KAKrystle N. Agans
Krystle N. Agans
BSBenjamin A. Satterfield
Benjamin A. Satterfield
KVKrista M. Versteeg
Krista M. Versteeg
Thomas W GeisbertThomas W Geisbert
Thomas W Geisbert
The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with high mortality in humans and nonhuman primates. A promising filovirus vaccine under development is based on a recombinant vesicular stomatitis virus (rVSV) that expresses individual filovirus glycoproteins (GPs) in place of the VSV glycoprotein (G). These vaccines have shown 100% efficacy against filovirus infection in nonhuman primates when challenge occurs 28–35 days after a single injection immunization. Here, we examined the ability of a rVSV MARV-GP vaccine to provide protection when challenge occurs more than a year after vaccination. Cynomolgus macaques were immunized with rVSV-MARV-GP and challenged with MARV approximately 14 months after vaccination. Immunization resulted in the vaccine cohort of six animals having anti-MARV GP IgG throughout the pre-challenge period. Following MARV challenge none of the vaccinated animals showed any signs of clinical disease or viremia and all were completely protected from MARV infection. Two unvaccinated control animals exhibited signs consistent with MARV infection and both succumbed. Importantly, these data are the first to show 100% protective efficacy against any high dose filovirus challenge beyond 8 weeks after final vaccination. These findings demonstrate the durability of VSV-based filovirus vaccines.